News
Gemini Bio to Distribute Scinus Products in the United States
* Gemini Bio adds Scinus Bioreactor to its portfolio
WEST SACRAMENTO, CA, and BILTHOVEN, The Netherlands, August 18, 2020 – Gemini Bioproducts, LLC (“Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced a distribution agreement with Scinus Cell Expansion Netherlands BV (“Scinus”). Customers will now be able to purchase the Scinus Cell expansion bioreactor system directly from Gemini Bio in the US.
Gemini Bio Launches the Moxi V™ Cell Analyzer
WEST SACRAMENTO, CA, July 14, 2020 – Gemini Bioproducts, LLC (“Gemini” or “Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners (“BelHealth”), announced the launch of the Moxi V™ for precision cell analysis.
Gemini Bio Opens New cGMP Facility
* New 25,000-square-foot state-of-the-art cGMP manufacturing facility in West Sacramento, CA, quadruples manufacturing capacity as the company continues to remain focused on serving the cell and gene therapy market
Gemini Bio Wins Federal Contract to Support COVID-19 Testing
* Will be increasing domestic production of reagents from its California facility, as well as its manufacturing footprint
WEST SACRAMENTO, CA, June 11, 2020 – Gemini Bioproducts, LLC (“Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), today announced the receipt of a federal government contract award to supply critical products in support of the high demand for COVID-19 testing.
Gemini Bio Announces Its Dedicated Effort to Help Support COVID-19 Research
* Gemini Bio’s Key Products are Supporting the Fight against COVID-19
WEST SACRAMENTO, CA, April 29, 2020 – Gemini Bioproducts, LLC (“Gemini” or “Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced its effort to help support COVID-19 research.
According to the WHO, there are over 200 countries with 2.9 million confirmed cases and over 202,000 confirmed deaths, as of the time of this release.
A Letter to our Customers
Our Role and Responsibility in Navigating COVID-19
During this time of unprecedented uncertainty, all of us here at Gemini Bio are concerned about the safety and well-being of our families, friends, colleagues, customers and suppliers.
Our hearts are with those who have been affected personally by the outbreak of coronavirus (COVID-19), as well as the many communities around the world that are facing extreme measures in the attempt to slow its spread.
Gemini Bio to Distribute Celartia Products in the United States
* Gemini Bio adds Celartia’s cell culture products to its portfolio
WEST SACRAMENTO, CA, and COLUMBUS, OH, January 8, 2020 – Gemini Bioproducts, LLC (“Gemini”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced a distribution agreement with Celartia, Inc. Effective immediately, customers can now purchase Celartia’s line of closed, single-use cell culture cassettes directly from Gemini.
Gemini Bio Announces the Acquisition of ORFLO Technologies
* ORFLO’s cell analysis offering to complement Gemini’s portfolio of cell culture reagents
WEST SACRAMENTO, CA, November 11, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading provider of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), today announced the acquisition of ORFLO Technologies (“ORFLO”), an innovative life sciences instrumentation company.
Gemini Bio-Products Announces Partnership with FroggaBio
* FroggaBio to distribute Gemini’s media and sera products across Canada
WEST SACRAMENTO, CA, October 1, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, is pleased to announce an exclusive distribution agreement for Canada with Toronto-based FroggaBio Inc. (“FroggaBio”). Starting today, customers in Canada will be able to purchase Gemini’s current and future products directly from FroggaBio.
Gemini Bio-Products Breaks Ground on New Facility
* New state-of-the-art cGMP manufacturing facility to open in Q1 2020
WEST SACRAMENTO, CA, September 25th, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced that it has broken ground on a new, state-of-the-art manufacturing facility in West Sacramento, CA. The company expects to relocate operations to the new facility during the first quarter of 2020.
Gemini Bio-Products to Distribute Nordmark products in the United States
* Gemini Bio-Products adds Nordmark’s Collagenase products to its portfolio
WEST SACRAMENTO, CA and HAMBURG, GERMANY, August 12, 2019 – Gemini Bioproducts, LLC (“Gemini”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced a distribution agreement with Nordmark Biochemicals, a division of Nordmark Arzneimittel GmbH & Co. KG (“Nordmark”). Launching this week, customers in the United States can now purchase Nordmark’s line of collagenase and neutral protease products directly from Gemini.